Combination Therapy With Bulevirtide, Peginterferon Alfa-2a Improves Outcomes In Patients With Chronic HDV Infection, Study Shows

Infectious Disease Advisor (8/20, Nye) reports, “Combination therapy with bulevirtide and pegylated interferon (peginterferon) alfa-2a improves outcomes in patients with chronic hepatitis D virus (HDV) infection, according to study results.” Investigators came to this conclusion after conducting “an open-label, multicenter, randomized, phase 2b trial” that included “adults aged 18 to 65 years with polymerase chain reaction (PCR)-confirmed HDV infection who had alanine aminotransferase (ALT) levels that were more than 1 but less than 10 times the upper limit of normal at baseline.” The findings were published in the New England Journal of Medicine.